Streetbeat News

Products Services

SNSE

Sensei Biotherapeutics has initiated the combination therapy arm of the Phase 1/2 clinical trial for SNS-101, a cancer treatment, with the first patient being dosed. The trial involves a combination of SNS-101 with Regeneron's Libtayo.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 11:32 am

CLF

Cleveland-Cliffs has announced an immediate increase in current spot market base prices for all carbon hot rolled, cold rolled and coated steel products. The company's minimum base price for hot rolled steel is now $750 per net ton.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 11:11 am

DTIL

Precision Biosciences has received a notice of allowance from the U.S. Patent and Trademark Office for engineered meganucleases that target human mitochondrial genomes. The patent, once issued, will expire in April 2024.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 11:10 am

IONS

Ionis Pharmaceuticals has entered into an agreement with Roche for two novel RNA-targeted programs for Alzheimer's and Huntington's diseases. The deal could potentially lead to new treatments for these neurodegenerative diseases.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 11:09 am

MIST

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced that results from a Phase 2 etripamil study will be presented at the American Heart Association (AHA) Scientific Sessions 2023. The study evaluated etripamil in emergency department patients with atrial fibrillation with rapid ventricular rate (AFib-RVR).

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 11:08 am

EVGN

Casterra Ag Ltd., a subsidiary of Evogene Ltd. (NASDAQ:EVGN), has shipped its first batch of high-yield, high-oil castor seeds from Brazil and Zambia to Africa. The shipment, valued at $1 million, is part of an $11.3 million purchase order from a leading oil and gas company.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 11:07 am

UBX

UNITY Biotechnology announced results from Part B of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD). The drug demonstrated a favorable safety profile and patients maintained vision gains. The company is now directing resources towards the DME program, where UBX1325 showed significant improvement in visual acuity. A Phase 2b study in patients with diabetic macular edema is expected to start in Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 11:06 am

CANF

Can-Fite BioPharma Ltd. (NYSE:CANF) announced that its study on the treatment of pancreatic carcinoma with Namodenoson has been accepted for a poster presentation at the AACR Special Conference on Pancreatic Cancer. The study showed significant growth inhibition in pancreatic carcinoma patient cells treated with Namodenoson. Can-Fite is planning to submit an exploratory Phase II protocol for approval in Israel and the U.S.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 11:05 am

AUGX

Augmedix has announced a new AI medical documentation product, Augmedix Go, which is a clinician-controlled mobile app. The product is designed to reduce the burden of administrative tasks on healthcare providers.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 11:02 am

DKNG

DraftKings is set to launch its online sportsbook in Kentucky on September 28.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 11:01 am